Immunity against pathogens is mediated through the induction of antigen-specific T helper (T H ) type 1 and type 2 lymphocytes. T H 1 immunity confers protection against intracellular pathogens and, when excessive, can lead to autoimmunity 1, 2 . Aberrant T H 2 cell activation against environmental antigens may induce allergy and asthma 3 . Activation and differentiation of T H immunity depends on interactions of T H cells with antigen-presenting cells, such as dendritic cells (DCs), and cytokines play a crucial role in this process.
Opn is a cytokine originally identified as the predominant transcript expressed by activated T cells 4, 5 . Opn-deficient (Spp1 -/-, also known as Opn -/-) mice exhibit reduced immunity to viruses 6 and other microorganisms 7 , develop milder experimental autoimmune encephalomyelitis [8] [9] [10] and are resistant to the development of autoimmune keratitis 6 , all T H 1-linked responses. Increased OPN expression has also been shown in affected tissues from individuals with rheumatoid arthritis, Crohn disease and multiple sclerosis [10] [11] [12] . Also, polymorphisms in the gene encoding OPN have been linked to the development of systemic lupus erythematosus and multiple sclerosis 13, 14 , suggesting a role in autoimmunity.
An important recent study has demonstrated that the intracellular form of Opn (Opn-i) is essential for interferon (IFN)-a production by plasmacytoid DCs (pDCs) upon viral infection or CpG oligonucleotide administration 15 . Additionally, recombinant OPN (rOPN) induces maturation of T H 1-polarizing human DCs in vitro 16 , and blockade of Opn-s reduces costimulatory molecule and class II molecule expression on human monocyte-derived DCs 17 . Moreover, Spp1 -/-mice exhibit reduced trinitrochlorobenzeneinduced migration of DCs to draining lymph nodes (DLNs) 18 . In contrast, rOpn administration inhibits bacterially induced DC migration 19 . Opn-i and Opn-s can therefore affect DC functions, which are crucial in determining the outcome of adaptive immunity.
Previous studies have focused on the role of Opn during T H 1 viral and autoimmune processes in which responses were ongoing by means of repetitive antigenic encounter 6, 8 . However, the effect of this cytokine during primary versus secondary antigenic encounters remains unclear. Moreover, the role of Opn in T H 2-mediated allergic responses, a rising health issue in industrialized countries 20 , has not been elucidated. Therefore, we investigated the in vivo effects of Opn-s in distinct phases of a T H 2 immune response and subsequent disease development, using an established mouse model of ovalbumin (OVA)-induced allergic airway inflammation 21 . We also examined whether the role of Opn-s was mediated by effects on DC subsets. By comparing the results obtained upon neutralization of Opn-s with those from Spp1 -/-mice, we studied the immunoregulatory activity of the Opn isoforms in T H 2 allergic responses and the disease phenotype.
RESULTS

Increased lung Opn expression in allergic disease
We investigated Opn expression during allergic T H 2 responses, using a mouse model of airway inflammation induced by OVA/alum sensitization followed by airway OVA challenges. There was upregulation of lung Opn expression in mice sensitized with OVA/alum as compared to PBS/alum (alum controls) (Fig. 1a) , localized mainly at sites of leukocytic infiltration and in bronchial and alveolar epithelial cells. Opn was also increased in lung homogenates from OVA-sensitized mice (Fig. 1b) .
In humans, lung biopsies from asthmatics had increased OPN expression in bronchial epithelial cells (ciliated epithelium) and inflammatory cells underneath the subepithelial membrane, as compared to healthy subjects (Fig. 1c) . The percentage of OPN-positive epithelial and subepithelial cells was also increased in asthmatic individuals compared to controls (Fig. 1d) .
Endogenous Opn-s is pro-inflammatory at sensitization
To investigate whether Opn-s participates during the induction of a T H 2 response, we administered a neutralizing antibody to Opn (or an isotype (Ig) control) before OVA/alum sensitization (Fig. 2a) . Following subsequent challenge through the airways with OVA, mice treated with the Opn antibody exhibited decreased numbers of bronchoalveolar lavage (BAL) eosinophils, lymphomononuclear cells (Fig. 2b) and decreased airway hyper-responsiveness (AHR), as compared to Igtreated mice, reaching levels similar to those of the alum controls (Fig. 2c) . Lung leukocytic infiltration and mucus secretion were also decreased (Fig. 2d) , accompanied by a decrease in the eosinophilspecific chemokine CCL11 in the lungs (Fig. 2e) .
Lung interleukin (IL)-4, IL-13 and IL-10 levels were decreased in mice treated with Opn-specific antibody (Fig. 2e) . Levels of IL-12, a T H 1 cytokine produced by DCs, macrophages and airway epithelial cells 22, 23 , were also decreased (Fig. 2e) . We attribute these decreases to the overall decrease in pulmonary inflammation. Cytokine levels in BAL exhibited similar patterns (data not shown).
We examined OVA-specific T H 2 responses by measuring cytokine levels in supernatants of DLN cell cultures stimulated ex vivo with OVA. Treatment with Opn-specific antibody resulted in decreased IL-4, IL-13 and IL-10 levels (Fig. 2f) . Levels of OVA-specific IgG1, IgG2a and IgE were decreased in mice treated with Opn-specific antibody (Fig. 2f) .
We observed decreased percentages of T H cells positive for T1/ST2, a T H 2 cell marker, in lung DLNs of mice treated with Opnspecific antibody, right after the first OVA challenge (Fig. 2g) and after three challenges (data not shown). Blockade of Opn-s resulted in decreased pulmonary levels of the T H 2 cell-specific chemokine CCL22 (Fig. 2g) .
Thus, antibody-mediated depletion of endogenous Opn-s during antigenic sensitization resulted in a reduction of T H 2 allergic responses and the consequent suppression of disease.
Endogenous Opn-s is anti-inflammatory during challenge
We investigated the role of endogenous Opn-s in secondary allergic responses by administering neutralizing antibody to Opn (or Ig control) before each OVA challenge in sensitized mice (Fig. 3a) . Opn-s neutralization increased the total number of infiltrating cells and eosinophils measured in the BAL (Fig. 3b) , AHR responses (Fig. 3c) , pulmonary inflammation ( Fig. 3d ) and mucus secretion (Fig. 3d) . Alum controls had lower inflammation and AHR ( Fig. 3b-d) .
Levels of IL-4, IL-13, IL-10, IFN-g and CCL11 in the lung were increased in mice treated with Opn-specific antibody (Fig. 3e) . It has been suggested that increased pulmonary IFN-g levels play a pathologic role in allergic airway disease [24] [25] [26] [27] . BAL cytokine levels were similarly increased in mice treated with Opn-specific antibody (data not shown).
In OVA-stimulated DLNs, blockade of Opn-s during challenge increased IL-13 and IL-10 and decreased IFN-g (Fig. 3f) . Levels of OVA-specific IgG1 were increased whereas OVA-specific IgG2a responses were decreased, indicative of a T H 2 shift (Fig. 3f) .
We observed increased percentages of DLN T1/ST2 + T H 2 cells following Opn-s neutralization, after the first intranasal OVA challenge (Fig. 3g) as well as after three OVA challenges (percentages of T1/ST2 + cells among gated T H cells: with antibody to Opn, 23.8-34.5%; with Ig control, 4.8-13.8%). In both cases, we observed increased levels of CCL22 and CCL17 in the lungs (Fig. 3g) . Overall, and in contrast to its effect at sensitization, blockade of endogenous Opn-s during antigenic challenge enhanced T H 2 allergic recall responses and exacerbated the disease phenotype.
Spp1 -/-mice have enhanced T H 2-mediated responses Spp1 -/-mice had increased numbers of BAL inflammatory cells and eosinophils compared to Spp1 +/+ (Fig. 4a) . Lung T H 2 cytokine and chemokine levels were similar (data not shown). However, Spp1 -/-mice have a predominantly C57BL/6 genetic background, which is thought to confer resistance to allergic inflammation, and deficiency in Opn may involve possible compensatory mechanisms.
OVA-stimulated DLN cells from Spp1 -/-mice produced increased IL-4, IL-13, IL-10 and IFN-g, as compared to cells from the wild-type mice (Fig. 4b) . In Spp1 -/-mice, OVA-specific IgG1 levels were increased whereas OVA-specific IgG2a responses were decreased, suggestive of a T H 2 shift (Fig. 4c) . We also observed increased levels of OVA-specific IgE in these mice (Fig. 4c) . OVA-specific IgE was increased in BALB/c mice treated with antibody to Opn during both the sensitization and challenge phases (Fig. 4d) , indicating no involvement of Opn-i.
Opn-s blockade at sensitization affects pDC numbers
To explore the effect of Opn-s neutralization at sensitization on final disease outcome, we examined early T H 2 responses. We treated BALB/ c mice with Opn-specific antibody or Ig control before sensitization with Alexa Fluor-OVA in alum, and examined CD11c + cell-driven responses. Cocultures of DLN CD11c + cells from Opn-s-neutralized mice with DO11.10 responder T cells produced lower levels of IL-4, IL-13 and IFN-g, as compared to those from Ig-treated mice (Fig. 5a ), suggestive of a reduced priming effect. We obtained similar results from OVA-stimulated whole DLNs (Opn-specific antibody versus Ig: 37.33 ± 2.46 versus 96.67 ± 7.92 pg/ml of IL-4; 717.3 ± 25.00 versus 962.4 ± 38.07 pg/ml of IFN-g).
It has been shown that two main subtypes of DCs participate in immune responses: conventional DCs (CD11c + B220 -or CD11c + B220 -Gr1 -cDCs), considered immunogenic, and pDCs, considered mainly regulatory [28] [29] [30] [31] . CD11c + PDCA-1 + /120G8 + Gr-1 + cells have been described as pDCs in allergic airway inflammation, exhibiting suppressive effects on T H 2 responses 28, 32, 33 .
Mice treated with Opn-specific antibody had increased percentages and total numbers of DLN CD11c + PDCA-1 + Gr-1 + pDCs (characterized also as CD11c + Gr-1 + B220 + ) and of Ag-loaded (Alexa Fluor-OVA + ) pDCs (Fig. 5b) . OVA uptake was not influenced, as the percentages of OVA + cells among pDCs were similar (approximately 52 ± 5% for Opn-s neutralization versus 47 ± 5% for Ig). We observed no differences in the percentages and numbers of cDCs (CD11c + B220 -Gr-1 -) or Alexa Fluor-OVA + cDCs (Fig. 5b) . The percentages of OVA + cells among cDCs were similar (approximately 45 ± 5% for Opn-s neutralization versus 51 ± 5% for Ig). The numbers of CD11c + cells within DLNs were similar among groups (per mouse: 65,420 ± 2,289 cells for Opn-s neutralization versus 65,250 ± 6,284 for Ig). Purified DLN CD11c + cells from Opn-sneutralized mice stimulated with CpG oligodeoxynucleotides produced increased levels of IFN-a, a defining characteristic of pDCs (refs. 28,34 and Fig. 5c ).
Spp1 -/-mice exhibited no significant enhancement of pDC recruitment in DLNs during priming, as compared to Spp1 +/+ mice (8,732 ± 2,900 versus 6,518 ± 2,100 cells per mouse, P ¼ 0.7170). We observed no differences in CD11c + cell recruitment (39,800 ± 4,800 versus 35,800 ± 9,200 cells per mouse). A study using a substantially different sensitization protocol, involving trinitrochlorobenzene administration, has demonstrated decreased migration of CD11c + cells to skin and DLNs in Spp1 -/-mice 18 . The discrepancies between this report and our findings might be due to different innate mechanisms.
A recent study has shown that pDCs suppress T H 2 responses 28 . To address whether the effects of Opn-s blockade during sensitization were mediated by the pDC population, we depleted pDCs (using the 120G8 antibody 35 ) before OVA/alum sensitization and Opn-s blockade in naive BALB/c mice. pDC depletion was successful, as shown by flow cytometric analysis of PDCA-1 + cells (Fig. 5d) . The Opn-specific antibody treatment had no effect on primary T H 2 responses in pDC-depleted mice, and after treatment, these responses were similar to those in Ig-treated, pDC-depleted mice. This was indicated by the IL-4, IL-13 and IFN-g levels and the OVA-specific proliferative responses (Fig. 5e) . In both groups, pDC-depleted mice exhibited increased IL-4, IL-13 and IFN-g levels (Fig. 5e) , suggestive of a regulatory role for pDCs, as previously described 28 . Isolated pDCs from DLNs in cocultures with DO11.10 T cells did not induce measurable cytokine levels, whereas cDCs induced cytokine release (IL-4 levels: 92 ± 10 pg/ml; IFN-g levels: 476 ± 20 pg/ml), suggesting that these cells might have immunogenic potential. We therefore concluded that the decrease in T H 2 priming observed after Opn-s neutralization was mediated by increased numbers of regulatory pDCs in DLNs.
Opn-s blockade at challenge affects cDC numbers We investigated cDC and pDC recruitment when Opn-s was neutralized during challenge (Fig. 3a, protocol) . There was an increase in total and Alexa Fluor-OVA + cDCs and pDCs in DLNs of mice treated with Opn-specific antibody (Fig. 5f) . OVA + cells among cDCs and pDCs were similar (approximately 47 ± 6% and 43 ± 5% for Opn-s neutralization, versus 53 ± 3% and 49 ± 6% for Ig). Opn-s blockade increased total numbers of CD11c + cells (data not shown). We obtained similar results on DC subsets following one, instead of three, intranasal challenges (data not shown). Of note, both triple and single challenges of mice treated with Opn-specific antibody enhanced AHR, increased the percentage of DLN T1/ST2 + T H 2 cells and IL-4 in OVA-stimulated DLNs (Fig. 3g and data not  shown) . Overall, we observed increased recruitment of cDCs and pDCs in lung DLNs, with the increase for cDCs being greater than that for pDCs.
To examine the role of pDCs in the above settings, we used pDCdepleted mice. These exhibited increased allergic responses in comparison to their respective non-pDC-depleted mice (Fig. 5g,h) , indicating a regulatory role for pDCs during secondary responses. Notably, in pDC-depleted mice, treatment with Opn-specific antibody, as compared to treatment with control Ig, increased total numbers of BAL cells (data not shown) and eosinophils as well as the levels of AHR, IL-13 and IL-10 in OVA-specific DLN responses (Fig. 5g,h ), suggesting that pDCs are not involved in the proallergic effect of Opn-s neutralization during challenge.
Cocultures of cDCs with DO11.10 T cells produced increased IL-4 and IL-13 levels, showing the T H 2-promoting potential of the cDCs (data not shown). Similar increases in cDC numbers have been linked to markedly enhanced inflammation 32 and T H 2 proliferation 36 . Overall, enhancement of T H 2 responses due to Opn-s blockade at challenge was influenced by the increased recruitment of immunogenic cDCs.
Administration of rOpn is protective at challenge rOpn administered along with OVA/alum during sensitization increased IL-13 and IFN-g levels in OVA-stimulated DLNs (Fig. 6a) , suggesting a pro-inflammatory role for Opn-s during T H 2 priming.
Intranasal administration of rOpn before OVA challenge decreased the total numbers of BAL cells, eosinophils and mononuclear cells (Fig. 6b) and AHR responses, to the levels seen in the controls (Fig. 6c) . Lung leukocytic infiltration, mucus secretion (Fig. 6d) and levels of IL-4, IL-13, IL-10, IFN-g, CCL11, CCL17 and CCL22 were also decreased, whereas IL-12 levels were increased (Fig. 6e) . BAL cytokines exhibited a similar pattern (data not shown).
OVA-stimulated DLN cells from rOpn-treated mice produced decreased IL-4, IL-13 and IFN-g levels (Fig. 6f) . OVA-specific IgG1 and IgE levels were decreased, whereas IgG2a levels were increased (Fig. 6g) . These results point to a suppressive role for endogenous Opn-s during secondary allergic airway responses.
DISCUSSION
Previous studies have demonstrated the impact of Opn on T H 1-associated immunity during ongoing immune responses against viral, bacterial and self antigens 6, 7, 15 . Our results point to dual and opposing effects of Opn-s on T H 2-mediated allergic airway disease: pro-inflammatory at primary systemic sensitization, and anti-inflammatory during pulmonary secondary antigenic challenge. Neutralization of Opn-s during initial antigenic encounter increased the recruitment of regulatory PDCA-1 + Gr-1 + pDCs in DLNs, which mediated a decrease in primary T H 2 responses. In contrast, Opn-s blockade during challenge enhanced T H 2 effector responses, mainly mediated by increased recruitment of T H 2-promoting cDCs in DLNs. Intranasal administration of rOpn during antigenic challenge reversed established T H 2 responses and conferred protection from allergic disease.
In agreement with a previous study 28 , our experiments revealed that pDCs were immunosuppressive for T H 2 responses. pDC depletion, before Opn-s neutralization, restored OVA/alum-driven responses, revealing that the dampening effect of Opn-s neutralization during priming was mainly mediated by pDCs. This initial pDC-mediated dampening in priming provided an explanation for the subsequent decrease in T H 2-mediated pathology following pulmonary challenge. Opn blockade was also accompanied by decreased IFN-g production whereas rOpn administration enhanced T H 2 priming and was accompanied by increased IFN-g production. IFN-g may participate in the Opn-s-mediated effect, particularly as decreased IFN-g production during OVA/alum sensitization reduces priming 24 . Opn-s neutralization at sensitization resulted in increased lung IFN-g levels following challenge. In this setting, IFN-g may exert an immunoregulatory role, associated with the increased number of pDCs at priming. In support of this idea, adoptive transfer of pDCs during sensitization enhances IFN-g levels and confers protection from allergic airway disease 29 , and induction of IFN-g-producing regulatory T cells reduces allergic airway inflammation 37 .
We were surprised to note the implicit pro-inflammatory effect of Opn-s during priming, as one would expect that blocking a T H 1 inducer 38 at the initial point of T H differentiation would upregulate T H 2 responses. However, it was rather Opn-s blockade during recall responses that resulted in enhanced allergic pulmonary inflammation and disease. We observed the same effect in mice treated with Opnspecific antibody during both the sensitization and challenge phases (data not shown and Fig. 4d ) and in Spp1 -/-mice, which developed increased T H 2 responses. Previous studies have demonstrated that during repetitive antigenic encounters, Spp1 -/-mice have decreased T H 1 immunity 4,6 and autoimmunity [8] [9] [10] . Our data imply that the previously demonstrated effect of Opn-s in T H 1/T H 2 balance operates predominantly during recall responses. Opn-s neutralization during challenge increased DLN cDC and pDC numbers. In allergic airway disease, the most powerful immunogenic potential of CD11c + cells 39 stems from cDCs (refs. 28,32) . For example, blockade of the C5a receptor during allergic airway inflammation increases the recruitment of cDCs, enhancing T H 2 responses 32 . However, we found that pDCs were suppressive during antigenic challenge. In the absence of pDCs, Opn-s blockade still enhanced T H 2 responses and allergic disease. Therefore, the increased induction of cDCs upon Opn-s neutralization provides an explanation for the exacerbation of T H 2-mediated disease. It is also likely that Opn-s neutralization induces a stronger T H 2 response, as Opn-s is known to affect antigen-presenting cells and thus influence the T H 1/T H 2 balance 6 . In support of this idea, local rOpn administration before challenge decreased T H 2 responses and increased IL-12 production.
To examine whether pDCs mediate the effect of Opn-s blockade, we used the 120G8 monoclonal antibody, which has been described as pDC specific and pDC depleting 28, 32, 35, 40, 41 . We found by flow cytometry that 120G8 strongly bound all pDCs from naive and OVA/alum-sensitized mice (data not shown). A recent study indicated that 120G8 binds to an epitope of the bone marrow stromal antigen-2 (ref. 42 ). This study also showed that bone marrow stromal antigen-2 is primarily expressed on all pDCs and to a lesser degree on some immune (plasma) cells, following activation by IFN or virus 42 . Thus, in addition to pDCs, we cannot exclude the contribution of other cell types to the Opn-mediated effect on T H 2 responses.
Comparing the results obtained from Opn-s neutralization to those from knockout of Spp1, we found that Opn-s plays a predominant role in allergic airway inflammation. However, considering the critical role of Opn-i in CpG-mediated pDC signaling 15 , its involvement in T H 2 regulation is probable. Administration of CpG, alone or in conjunction with allergens, in the lungs of allergic mice reversed established inflammation, possibly through an effect on IFN-a production by pDCs (refs. 43,44) . Notably, both isoforms affect pDCs: Opn-s regulates pDC recruitment in allergic response, as described here, whereas Opn-i is essential for functions of pDCs in viral immunity 15 .
Increased Opn expression in allergic airway disease may be part of an inherent protective mechanism, as suggested by the fact that the disease was exacerbated following Opn-s blockade at challenge. In fact, it was recently shown that the gene encoding OPN is critically upregulated during bee-venom immunotherapy 45 . In our experiments, administration of rOpn at challenge provided protection from allergic disease. This was mainly mediated through a shift toward an antiallergic T H 1, as shown by increased levels of IL-12 and OVAspecific IgG2a. Intranasal administration of IL-12 during challenge suppresses airway disease 46 . Our data show that, as with IL-12, rOpn is an effective regulator of allergic airway disease.
The variable effect of Opn-s on T H 2 immunity points once more to cytokines playing opposing roles depending on the phase and milieu of the immune response. The effects of Opn-s on pDC biology as well as their contribution to autoimmunity remain to be elucidated. In g, serum levels of OVA-specific-IgE (P ¼ 0.0589), IgG1 (P ¼ 0.0703) and IgG2a (**P ¼ 0.0045). Data are expressed as mean ± s.e.m. n ¼ 6-8 mice per group in three independent experiments. Unpaired Student's t-test for all statistical analyses.
METHODS
Mice. We purchased BALB/c and OVA-specific T-cell receptor-transgenic DO11.10 (Tcr-TG-DO11.10) mice from the Jackson Laboratory. We backcrossed Spp1 -/-mice onto the C57BL/6 background for seven generations. Figure 5f , BALB/c mice were sensitized with OVA/alum i.p. on days 0 and 12, and, starting on day 18, were challenged intranasally with one or three doses of 0.5 mg Alexa Fluor-OVA. We administered Opn-specific antibody or Ig control (40 mg per mouse) i.p. 2-3 h before challenge. The data depicted in Figure 5g ,h are from BALB/c mice sensitized with 10 mg of OVA/ alum i.p. on days 0 and 12 and then given 225 mg of 120G8 pDC-depleting antibody or Ig control (i.p.) daily from days 17 to 20. Mice also received 20 mg of Opn-specific antibody or Ig control i.p. daily, 2-3 h before OVA challenge, from days 18 to 20. Mice were killed 40 h after the final challenge. In Figure 6a , the data are from BALB/c mice given 4 mg of mouse rOpn (R&D Systems) or PBS i.p., and then, 2-3 h later, sensitized i.p. with 0.1mg Alexa Fluor-OVA/ alum. For the data in Figure 6b -g, we sensitized BALB/c mice with OVA/alum i.p. on days 0 and 12 and then challenged them intranasally with 0.5 mg Alexa Fluor-OVA from days 18 to 20. We administered rOpn (2.5 mg per mouse) or PBS i.p. 2-3 h before challenge. Mice were killed 40 h after the final challenge.
AHR and airway inflammation. We measured AHR, a clinical measurement of asthma, as enhanced pause (Penh) and BAL inflammatory cells, as previously described 47 . We stained paraffin-embedded sections with hematoxylin & eosin (H&E) or Periodic-Acid-Schiff (PAS), as previously described 21 .
Human subjects. We performed flexible bronchoscopy on asthmatics, classified and treated according to the Global Initiative for Asthma guidelines (one mild intermittent, one moderate and four severe), and nine healthy volunteers. We took biopsies as previously described 48 . The study was approved by the Sotiria Hospital Ethics Committee, and individuals signed an informed-consent form.
Immunohistochemistry. We immunostained paraffin-embedded sections as previously described 47 . We used antibodies to human OPN (MAB-1433, R&D Systems) and mouse Opn (AF-808, R&D Systems). For a control, we used matched isotype IgG (R&D Systems).
Cell culture, proliferation and cytokine analysis. We obtained lung homogenates as previously described 47 . We used a previously described method 49 to isolate cells from DLNs (mediastinal, following intranasal treatment, or inguinal and axillary following i.p. treatment). We cultured DLN cells, alone or with CD4 + T cells (Dynal) from DO11.10 mice, with 125 mg/ml OVA for 48 h. We cocultured CD11c + cells purified from DLNs (Miltenyi Biotec) with T H cells from DO11.10 mice and 125 mg/ml OVA, for 48 h. For pDC and cDC isolation, a combination of the above-described method with the pDC isolation kit (Miltenyi Biotec) was used. We performed proliferation assays as previously described 49 . To measure cytokines and chemokines, we used ELISA kits for IL-4, IL-10, IFN-g and IL-12 (BD Biosciences) and IL-13, Opn, CCL11, CCL22 and CCL17 (R&D Systems). We used a newer kit for IL-13 in pDC depletion experiments (R&D Systems). We cultured CD11c + cells with 0.2 mg/ml CpG oligodeoxynucleotides (5¢-TCCATGACGTTCCTGATGCT-3¢) or control GpC (5¢-TCCATGAGCTTCCTGATGCT-3¢) (MWG, Biotech), synthesized as described 31 . After 24 h, we measured IFN-a, by ELISA (PBL Biomedical Laboratories).
Serum antibody concentration. We measured OVA-specific IgE, IgG1 and IgG2a antibodies as described 50 .
Flow-cytometric analysis. We stained live DLN cells (7AAD -, BD Biosciences) with conjugated antibodies to CD4, CD3, CD11c, B220, CD11b, Gr-1, PDCA-1 (BD Biosciences) and T1/ST2 (MD Biosciences). To perform the FACS analysis, we used a Coulter cytometer (Cytomics, FC 500).
